| Abstract: | AIM: To observe the synergistic and attenuating effects of Qiongyugao on pancreatic cancer mice with chemotherapy and to explore its possible mechanism. METHODS: C57BL/6 mice (n=50) were randomly divided into normal group, model group, gemcitabine treatment group, Qiongyugao treatment group, and combined treatment (gemcitabine+Qiongyugao) group. The pancreatic cancer mouse xenograft model was established by subcutaneous inoculation with pancreatic cancer Panc02 cells among the mice in model group and 3 treatment groups. Normal saline, gemcitabine, Qiongyugao and gemcitabine plus Qiongyugao were also used accordingly. The tumor growth curve, blood routine and tumor markers were observed in each group. Furthermore, flow cytometry was used to detect the expression of Th1/Th2 and Th/Treg in peripheral blood of the mice. RESULTS: Subcutaneous vaccination with Panc02 cells successfully established a transplanted tumor model of pancreatic cancer. Compared with model group, Qiongyugao, gemcitabine and the combination of the 2 drugs inhibited tumor growth (P<0.05), and decreased the concentration of carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) (P<0.05). Qiongyugao decreased the ratio of Th1/Th2 and Th17/Treg, and increased the white blood cell (WBC), red blood cell (RBC) and platelet (PLT) counts and hemoglobin (HGB) content in gemcitabine treated mice (P<0.01). CONCLUSION: Qiongyugao may have a certain therapeutic effect on pancreatic cancer and produce certain synergistic and attenuating effects on gemcitabine chemotherapy. |
